Chugai is a pharmaceutical company and a member of Roche Group. Chugai’s mission is to dedicate itself to adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.
In the area of global health, Chugai participates in the Global Health Innovative Technology Fund (GHIT Fund), which aims to conquer infectious diseases in developing countries, and Access Accelerated, which conducts measures for people in those same countries who are living with noncommunicable diseases (NCDs).
In December 2014, Chugai announced its participation in the GHIT Fund and contributed capital. It also decided to undertake a specific drug development program using its innovative discovery technologies and research resources.
As a partner in the GHIT Fund, Chugai expects that furthering the development of new medical technologies will go beyond fulfilling its basic social responsibility, leading to the promotion of health and sound economic growth in developing countries.
In partnership with the World Bank Group and the Union for International Cancer Control (UICC), Access Accelerated is working to achieve the UN Sustainable Development Goal 3 target of reducing premature deaths due to NCDs by one-third by 2030. Chugai contributes to improving access to healthcare in low and middle income countries.